News

Ideas That Generate Results

According to a new research report by RNCOS entitled,“Preventive Asthma Drug Market Outlook 2020”, the global market for preventive asthma drugs is likely to expand with a CAGR of 4.7% from 2014-2020. Growing preference towards preventive healthcare, mounting asthma cases owing to rising pollution levels and increasing investment in research and development are key influencing factors supporting the growth of this industry. The demand of preventers is of considerable rise both in the developed and developing regions owing to the rising allergies.
 
Popular pharmaceutical manufacturers such as GlaxoSmithKline, AstraZeneca, Novartis, Roche and others are increasing their R&D expenditure for developing preventive respiratory drugs. According to the American Academy of Allergy, Asthma, and Immunology, asthma is broadly classified into four types: exercise-induced, allergic, occupational, and childhood. Allergies induced asthma grabs the highest attention among researchers. This is due to the increase in airborne pollutants, and climate changes that trigger a rise in pollen levels. This causes shortness of breath, wheezing and chest tightness leading to asthma. The drug type used against allergy induced asthma are inhaled corticosteroids Seretide/Advair, Flixotide/Flovent, Pulmicort among others.
 
Research Analysis and Highlights
 
The report is spreaded in 45 pages and provides an in-depth research and rational analysis of the current status and future prospect of the Global Preventive Asthma Drugs industry. The report provides a clear picture of the factors driving the industry growth, and challenges faced by the industry. In addition to this, the study includes industry developments that have occurred during past two years. The report further highlights market segmentation of the industry by types of drugs and geography. Separate section is allotted to recommendations to boost the global industry. With special emphasis on competitive landscape and dominant players in the market, the research provides valuable information to the investors who are looking to enter in this market.
 
Some of the key highlights of the report include the following:
 

     - sCombined Therapy Benefitting Asthma Patients
     - Monoclonal Antibody: An Emerging Effective Treatment for Asthma
     - Inhaled Corticosteroids Continued to be Preferred Preventive Treatment for Asthma
     - GSK, AstraZeneca and Merck Leading PAD Market

 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM798.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm